Athyrium Capital Management, LP

Add to watchlist

$97.9 Million is the total value of Athyrium Capital Management, LP's 2 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 33.3% .

All

			Value		Shares		↓ Weighting
		AEGERION PHARMACEUTICALS INCnote 2.000% 8/1	$86,826,000	-2.7%	117,737,000	0.0%	88.73%	+3.2%
KALA		KALA PHARMACEUTICALS INC	$11,027,000	+69.1%	1,333,333	0.0%	11.27%	+79.4%
	Exit	PTC THERAPEUTICS INCnote 3.000% 8/1	$0	–	-8,067,000	-100.0%	-7.78%	–

Original filings

The following EDGAR filing(s) were analyzed to create this report:

View 13F-HR filed 2019-05-15

Signatures

The EDGAR filing(s) were signed by:

Andrew Hyman — Chief Operating Officer and General Counsel

Top long-term holdings

Name	Quarters owned	Latest quarter owned	Max weighting
Amryt Pharma PLC	10	Q1 2023	46.3%
Progenity Inc.	9	Q4 2022	69.2%
Progenity Inc.	8	Q3 2023	39.2%
RVL PHARMACEUTICALS PLC	8	Q3 2023	11.5%
Societal CDMO Inc.	8	Q4 2022	3.1%
Omeros Corp	7	Q3 2023	39.3%
CAREMAX INC	7	Q4 2022	27.5%
Omeros Corp	7	Q3 2023	9.9%
PUMA BIOTECHNOLOGY INC	7	Q3 2023	4.2%
AEGERION PHARMACEUTICALS INC	6	Q1 2019	88.7%

View Athyrium Capital Management, LP's complete holdings history.

Latest significant ownerships (13-D/G)

Athyrium Capital Management, LP Q1 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
	Filed	Shares	Percentage
PROGENITY, INC.	August 27, 2021	4,211,977	2.7%

View Athyrium Capital Management, LP's complete significant-ownership history.

Latest filings

Type	Filed
13F-HR	2024-02-14
13F-HR	2023-11-14
13F-HR	2023-08-14
13F-HR/A	2023-05-16
13F-HR	2023-05-15
13F-HR	2023-02-14
13F-HR	2022-11-14
13F-HR	2022-08-15
13F-HR	2022-05-16
13F-HR	2022-02-14

View Athyrium Capital Management, LP's complete filings history.

All filings

View complete filings history.

Compare quarters

Export Athyrium Capital Management, LP's holdings